

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number
WO 01/34116 A2

(51) International Patent Classification⁷: **A61K 9/127**,
35/78, 31/352, 31/222, 31/045, A61P 35/00

KOKKINOPOULOS, Demetrios; 26 Naxou Str.,
GR-145 62 Kifissia (GR).

(21) International Application Number: PCT/GR00/00033

(74) Agent: **PAPACONSTANTINO**, Helen, G.; 2 Coumbari
Street, GR-106 74 Athens (GR).

(22) International Filing Date:

8 November 2000 (08.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

990100387

8 November 1999 (08.11.1999)

GR

(81) Designated States (*national*): AE, AG, AL, AM, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ,
EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PL, RO, RU, SD, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(71) Applicant: **P.N. GEROLYMATOS S.A.** [GR/GR]; 13
Askliou Street, GR-145 68 Kryoneri Attica (GR).

Published:

— Without international search report and to be republished
upon receipt of that report.

(72) Inventors: **DEMETZOS, Constantinos**; 523 Grigo-
riou Labraki Str., GR-187 57 Keratsini (GR). **DIMAS**,
Constantinos; 74-78 Kanari Str., GR-185 38 Piraeus
(GR). **ANGELOPOULOU, Demetra**; 33 Kalirois Str.,
GR-145 65 Ekali (GR). **ANASTASSAKI, Thalia**; 27
Hatziantoniou Str., GR-151 24 Amaroussion (GR).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **PHARMACEUTICAL FORMULATIONS COMPRISING LABDANES FOR THE TREATMENT OF TUMORS OR
LEUKEMIAS**

(57) Abstract: The present invention relates to novel compositions based on hydrated lipidic lamellar phases or liposomal com-
positions, prepared by combining different lipid molecules, synthetic and/or from natural sources, said compositions comprising
at least one of a) labd-13-ene-8 α , 15-diol and/or derivatives thereof; b) labd-14-ene-8, 13-diol or derivatives thereof; c) 3 β -hy-
droxy-labd-14-ene-8, 13-epoxy and/or derivatives thereof; d) a plant extract containing the aforementioned labdenes or derivatives
thereof. The compositions of the invention exhibit cytotoxicity against cancerous cells and are utilized for the treatment of tumors
and leukemias.

WO 01/34116 A2


PHARMACEUTICAL FORMULATIONS COMPRISING LABDANES FOR THE
TREATMENT OF TUMORS OR LEUKEMIAS.

I. INTRODUCTION

5 The present invention relates to novel
compositions based on hydrated lipidic lamellar phases or
liposomal compositions, prepared by combining different
lipid molecules, synthetic and/or from natural sources, said
compositions comprising at least one of a) labd-13-ene-8a,
10 15-diol and/or derivatives thereof; b) labd-14-ene-8, 13-
diol or derivatives thereof; c) 3 β -hydroxy-labd-14-ene-8,
13-epoxy and/or derivatives thereof, d) a plant extract
containing the aforementioned labdenes or derivatives
thereof. The compositions of the invention exhibit
15 cytotoxicity against cancerous cells and are utilized for
the treatment of tumors and leukemias.

II. BACKGROUND OF THE INVENTION

 A very large number of diterpenoids possessing a
20 labdane skeleton (Figure 1)



30 occur in nature (Connolly, J.D.; Hill, R.A Dictionary of
Terpenoids, Chapman and Hall: London 1991). The interest in

studying labdanes is heightened due to the wide range of biological activities of these compounds (Singh, M.; Pal, M.; Sharma, R.P. *Planta Med.*, 1999, 65, 2-8.). They comprise a decalin system and a C-6 ring, which may be open or closed with an oxygen atom, as in manoyl oxide and its derivatives. Labdanes have been isolated from several plant families, such as Asteraceae, Labiateae, Cistaceae, Pinaceae, Cupressaceae, Taxodiaceae, Acanthaceae, Annonaceae, Caprifoliaceae, Solanaceae, Apocynaceae, Verbenaceae and Zingiberaceae. In addition they have been isolated from marine algae of the genus *Laurence*, from *Taonia atomaria* and from the red alga *Chondria tenuissima*.

The conifers are an important source of diterpenoids. Several labdanes have been detected in the neutral fraction of the oleoresin of *Araucaria excelsa*, including manool as well as nor-labdanes (Caputo, R.; Mangoni, L.; Monaco, P. *Phytochemistry*, 1972, 11, 839-840). A variety of biological activities have been associated with labdane diterpenes including antibacterial, antifungal, antiprotozoal, enzyme induction, anti-inflammatory modulation of immune cell functions, as well as cytotoxic and cytostatic effects against human leukemic cell lines. (K. Dimas et al. *Planta Med.* 1998, 208-211; K. Dimas et al. *Leukemia Res.* 1999, 217-234; K. Dimas et al. *Anticancer Res.* 1999, 4065-4072). In addition to the (antimicrobial, enzyme and endocrine related) properties mentioned above, it is interesting that many labdane type diterpenes also exhibit significant properties against cancer cells. A number of labdane type diterpenes tested exhibited remarkable antiproliferative and cytotoxic activities (Itokawa, H. et al. *Planta Med.* 1988, 311-315; K. Dimas et al. *Planta Med.* 1998, 208-211; K. Dimas et al. *Leukemia Res.* 1999, 217-234; K. Dimas et al. *Anticancer Res.* 1999, 4065-4072).

Labdane furanoids, and forskolin derivatives are the subject of several patents and applications, including European Patent Application 93103605.7; International Patent Publication No. WO 97/45099; International Patent
5 Publication No. WO 91/02525; and International Patent Publication No. WO 85/03637.

Liposomes, or phospholipid vesicles, are self-assembled colloidal particles that occur naturally and can be prepared artificially (Lasic, D.D. Liposomes: from
10 Physics to Applications. Elsevier), as shown by Bangham and his students in the mid-1960s (Bangham, A.D. ed. (1983) Liposomes Letters, Academic Press). At first, they were used to study biological membranes; several practical
15 applications, most notably in drug delivery, emerged in the 1970. Today, they are a very useful model, reagent and tool in various scientific disciplines, including mathematics and theoretical physics, biophysics, chemistry, colloid science, biochemistry and biology. Liposomes were introduced as drug-
20 delivery vehicles in the 1970s. Early results were, however, rather disappointing, owing mainly to their colloidal and biological instability, and their inefficient and unstable encapsulation of drug molecules. Their utility was improved following basic research that increased our understanding of
25 their stability and interaction characteristics. In parallel, several pharmaceutical enterprises were founded that survived the decline in the controversial appreciation of liposomes in the 1980s and early 1990s and, eventually, put several commercial products on the market. At present, these include antifungal and anti-cancer preparations that
30 compare favorably to existing treatments, but a recent renaissance in liposome research is promising many more products to come.

In the scientific literature, there is reference to a great number of liposomic pharmaceutical forms. Many of these are in the clinical study stage and some other have been already registered and marketed. Among the medicines formulated in liposomic form, are econazole, amfotericin B, minoxidyl and some anticancer and antiviral medicines, which are in the clinical study stage.

III. DETAILED DESCRIPTION OF THE INVENTION

It has been found that naturally occurring labdanes, such as labd-13-ene-8 α , 15-diol, labd-14-ene-8, 13-diol, and 3 β -hydroxy-labd-14-ene-8, 13-epoxy, exhibit biological properties in their pure state (Dimas et al., Planta Med. 1998) and may be useful as novel pharmaceutical and medicinal agents. The present invention deals with preparation of hydrated lipidic lamellar phases or liposomes particularly conventional and/or PEGylated and/or protein conjugated, containing the above compounds and their derivatives or plant extracts containing them, which are part of this invention. The compositions of the invention are useful for the treatment of neoplastic diseases.

As used herein the term "alkyl" refers to a straight or branched, saturated hydrocarbon containing from one to about twelve carbon atoms such as, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl, wherein one or more of the hydrogen atoms may be substituted.

As used herein the term "alkenyl" refers to a straight or branched hydrocarbon containing from one to about twelve carbon atoms where at least one carbon-carbon bond is unsaturated such as for example, vinyl, allyl and butenyl, wherein one or more of the hydrogen atoms may be substituted.

As used herein the term "alkynyl" refers to a straight or branched hydrocarbon containing from one to about twelve carbon atoms where at least one carbon-carbon bond is doubly unsaturated such as for example, acetylene, propynyl and butynyl, wherein one or more of the hydrogen atoms may be substituted.

As used herein the term "cycloalkyl" refers to a cyclic hydrocarbon containing from three to about twelve carbon atoms such as, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, wherein one or more of the hydrogen atoms may be substituted.

As used herein the term "aralkyl" refers to a straight or branched, saturated hydrocarbon containing from one to about twelve carbon atoms, which is substituted with an aromatic ring such as, for example, benzyl and phenethyl, wherein one or more of the hydrogen atoms may be substituted.

As used herein the term "heterocyclyl" refers to a cyclic hydrocarbon, wherein at least one carbon atom has been replaced by a heteroatom such as, for example, nitrogen, oxygen or sulfur, containing from three to about twelve atoms such as, for example, furan, pyran and imidazole.

As used herein the term "dialkylaminoalkyl" refers to a straight or branched, saturated hydrocarbon containing from one to about twelve carbon atoms, which is connected to a tertiary amino group containing two alkyl groups such as, for example, diethylaminoethyl. Preferably, the dialkylaminoalkyl group is present as the acid addition salt resulting from reaction with either an inorganic or organic acid.

As used herein the terms "alkylthioketones", "alkenylthioketones", "alkynylthioketones",

"cycloalkylthioketones", "aralkylthioketones" and "heterocyclothioketones" refer to a thioketone connected to a further radical.

As used herein the terms "alkylcarbonyl", "alkenylcarbonyl", "alkynylcarbonyl", "cycloalkylcarbonyl" and "aralkylcarbonyl" refer to a carbonyl connected to a further radical.


As used herein the term "sugars" refers hexoses or pentoses in their pyranose or furanose state or disaccharides containing hexose-hexose, pentose-pentose, hexose-pentose or pentose-hexose in their pyranose or furanose state. These sugars may be substituted with amino or halogen groups, preferably chlorine, bromine or iodine.

1. Labdanes of the Invention

The labdanes of the present invention include:

A. Formula I,


LABD-13-ENE-8 α ,15-DIOL (I)



Wherein R wherein R is selected from the group consisting of H, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, cycloalkylcarbonyl, aralkylcarbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, dialkylaminoalkyl, alkylthioketones, alkenylthioketones, alkynylthioketones, cycloalkylthioketones, aralkylthioketones, heterocyclylthioketones and sugars.

B. Formula II


LABD-14-ENE-8, 13-DIOL (II)



II

Wherein R wherein R is selected from the group consisting of H, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, cycloalkylcarbonyl, aralkylcarbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, dialkylaminoalkyl, alkylthioketones, alkenylthioketones, alkynylthioketones, cycloalkylthioketones, aralkylthioketones, heterocyclylthioketones and sugars.

C. Formula III

3 β -HYDROXY-LABD-14-ENE-8, 13-EPOXY

III

Wherein R_1 is =O, OR_2 , or a halogen selected from the group consisting of chlorine, bromine or iodine. R_2 is selected from the group consisting of H, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, cycloalkylcarbonyl, aralkylcarbonyl, alkyl, alkenyl, alkynyl, cycloalkyl,

aralkyl, dialkylaminoalkyl, alkylthioketones, alkenylthioketones, alkynylthioketones, cycloalkylthioketones, aralkylthioketones, heterocyclylthioketones and sugars.

5 For the above derivatives, when R or R² is dialkylaminoalkyl, the diethylaminoethyl group is preferred and a suitable acid addition salt is derived from inorganic or organic acid i.e hydrochloride, hydrobromide, sulfate, phosphate, acetate, oxalate, tartrate, citrate, maleate or
10 fumarate. When R or R² is aralkyl, phenylalkyl groups can be substituted by 1, 2 and 3 identical or different substituents such as halogen, C1-C3-alkyl, C1-C3-alkoxy, hydroxy, nitro, amino, trifluoromethyl, cyano and azido.

In addition to the optical centers of the labdane
15 nucleus, the substituents may also have chiral centers, which contribute to the optical properties of the compounds to the invention. This invention embraces all the optical isomers and racemic forms of the compounds according to the invention where such compounds have chiral centers in
20 addition to those of the labdane nucleus.

The labdanes, labd-13-ene 8 α , 15-diol (I) and its derivative labd-13-ene 8 α , 15-yl acetate as well as 3 β -substituted-labd-14-ene-8, 13-epoxy when 3-substitue is hydroxy (OH) (III) or acetoxy (O Ac) groups have been
25 detected into the extracts and essential oils of the plant *Cistus creticus* subsp. *eriocephalus*, and then identified for the first time (Anastassaki, Demetzos et al. *Planta Med.* 1999 735-739) using GC-MS (Gas Chromatography-Mass Spectrometry) methodology. The above compounds have been
30 isolated in their pure state and their structures have been determined using spectroscopic methods, mainly NMR (Nuclear Magnetic Resonance) (Demetzos et al. unpublished data). The labdane, labd-14-ene-8, 13-diol (II) namely sclareol has

been isolated from Clary sage (*Salvia sclarea* Linn), as well as from *Cistus incanus* subsp. *creticus* (Ulubelen A., et al. *Phytochemistry* 1985, 1386; Demetzos C., Ph. D Thesis, Athens 1990).

5 2. Liposome Preparation

The present invention provides liposomal formulations comprising one or more of the above described compounds. Any liposomal formulation known to those of skill in the art may be applied to the above described labdane compounds.

The lipids useful for the preparation of hydrated lipidic lamellar phases or liposomes comprising labdanes and/or their derivatives are described. The lipid molecules may be, but are not limited to, naturally occurring lipids such as HSPC (hydrogenated soy phosphatidylcholine), EPC (a mixture of saturated and unsaturated lipids from eggs) SPS (soy phosphatidylserine as sodium salt) and lipids isolated from natural sources (i.e. plants, marine organism and animal tissues) as mixtures of lipids and some synthetic lipids like: DSPC (distearoylphosphatidylcholine), DMPC (dimyristoylphosphatidylcholine) and DPPC (dipalmytoylphosphatidylcholine) DOPC (dioleoylphosphatidylcholine), which are saturated esters of phosphatidylcholine. Polyethylene glycol (PEG)-lipid conjugates have been used to improve circulation times for liposomes encapsulated drugs and may be used in compositions of the present invention.

PEG-PE(phosphatidylethanolamine) have been used for preparing long circulating liposomes, and may be used in the compositions of the invention. PEG-lipid conjugates may also be used. Examples of PEG-lipid conjugates include 1,2-Diacyl-sn-glycero-3-Phosphoethanolamine -N-[Methoxy(Polyethylene Glycol)-2000], in which the term acyl

represents myristoyl , palmitoyl, stearyl and oleoyl groups.

Conventional or PEGylated liposomes containing cholesterol or cholic acid (transferosomes) in various concentrations by combining different phospholipids may also be utilized in the compositions of the invention.

Cholesterol may regulate the stability of liposomes and therefore the inclusion of cholesterol in liposomes may be beneficial for the controlled release of the liposome associated compounds, such as the labdanes of the present invention. Because of the prolonged liposome circulation in blood and enhanced stability due to steric stabilization by surface-grafted polymers, the polymer-coated long-circulating liposomes have been referred to as sterically stabilized liposomes (Papahadjopoulos, D. et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 88. 11460-11464). The optimal stability of this type of liposome is obtained at around 5 mol% of PEG-lipid (PEG molecular weight 2000 Da (Lasic, D.D. (1994) Angew. Chem, Int. Ed. Engl. 33, 1785-1799).

Liposomes may be prepared by combining different synthetic lipids or natural lipids isolated from natural sources, such as lipids from plants and/or marine organisms and/or animal tissues. Liposomes may be prepared not only by combining different phospholipids but also by combining phospholipids with different levels of cholesterol and cholic acid (in its salt form).

Immunoliposomes are either conventional or sterically stabilized liposomes, which have specific proteins on their surface acting as recognition centers.

Immunoliposomes may be prepared using the noncovalent biotin-avidin method and covalent bonding of proteins with the liposomes surface.

The PE derivatives of PEG with a terminal carbonyl group (Di acyl-PE-PEG-COOH) or with a terminal maleimidyl group (Di acyl-PE-PEG-Mal) may be synthesized according to K. Maruyama et al. B.B.A (1995) 1234, 74-80.

5 The use of immunoliposomes in the treatment of tumors resulted in a marked improvement in the drugs efficacy not only in comparison to the drug on its own but also compared to conventional liposomes.

10 Liposomes of different sizes and characteristics require different methods of preparation. The most simple and widely used method for preparation of MLV (Multilamellar Vesicles) is the thin-film hydration procedure in which a thin film of lipids is hydrated with an aqueous buffer at a temperature above the transition temperature of lipids. For
15 lipophilic compounds such as the labdanes and their derivatives part of this invention, the REV (Reverse-Phase Evaporation), techniques is more suitable for the compounds encapsulation. In brief, different MLV liposomes composed of DSPC, DPPC, DMPC, DOPE, Soy Phosphatidylserine as sodium
20 salt with or without cholesterol or cholic acid (as a salt) and PEGylated liposomes with or without cholesterol or cholic acid (as a salt) may be prepared by hydration with a buffer such as TES (N-tris-[hydroxymethyl] methyl 2-amino ethanesulfonic acid), MES (2-[N-morpholino] ethanesulfonic
25 acid), HEPES (N-[2-hydroxyethyl]-piperazine-N-2-ethanesulfonic acid), after the removal of the organic solvent (Chloroform) in which labdanes and their derivatives have been dissolved.

30 The removal of the organic solvent in vacuum or under an inert gas results in the hydration of the lipids which form into multilayer liposomes upon vigorous shaking of the lipid film in an aqueous solution. The lipophilic labdanes incorporate into lipid bilayers, while the

hydrophilic derivatives thereof are encapsulated in the liposomes. The aqueous medium used in hydrating the dried lipid film is preferably pyrogen free. The medium preferably contains physiological salt, such as NaCl, sufficient to
5 produce a near-physiologic osmolarity (about 300 mOs).

The liposome dispersion is sized to achieve a size distribution of vesicles in a size range preferably between about 0.1 and 0.5 microns. The sizing serves to eliminate larger liposomes and to produce a defined size range having
10 optimal pharmacokinetic properties. One preferred method for achieving the desired size distribution of liposome sizes is by extrusion of liposomes through a small-pore polycarbonate membrane sizes whose selected pore sizes such as 0.1, 0.2 or 0.4 microns, correspond approximately to the size
15 distribution of liposomes after one or more passes through the membrane. Typically the liposomes are extruded through the membranes several times until the size distribution stabilises (Shokai et al, 1978). The liposomes dispersion is further treated to remove free labdanes, i.e. labdanes which
20 are not intimately associated with the lipid bilayers. The suspension can be pelted by high-speed centrifugation after dilution, leaving free labdanes and very small liposomes in the supernatant. Another method uses gel filtration by molecular sieve chromatography to separate liposomes from
25 free labdanes. Sephadex (G-75) gel filtration was used in order to remove the free labdanes.

In one embodiment, the final encapsulated liposomal labdane dispersion has the following characteristics:

- 30 1. Liposome sizes range between about 0.1 to 0.25 microns
2. Liposome-encapsulated labdanes about 80%-90%
3. The dispersion has a lipid concentration of at least 5 mg total lipid/ml, and near physiological osmolarity.

The dispersion may be sterilized by filtration through a conventional 0.22-micron depth filter.

3. Therapeutic Use of The Compositions of the Invention

5 The formulations of the invention are useful for treating mammalian cancers or conditions related thereto. By "treating" it is meant that the formulations are administered to inhibit or reduce the rate of cancer-cell proliferation in an effort to induce partial or total
10 remission, for example, inhibiting cell division by promoting microtubule formation. For instance, the formulations of the invention are useful for treating, but not limited to, cancers of the blood, breast, lung, ovary, prostate, head, neck, brain, testes, kidney, pancreas, bone,
15 spleen, liver, and bladder; AIDS-related cancers, such as Kaposi's sarcoma; leukemia (e.g., acute leukemia such as acute lymphocytic leukemia and acute myelocytic leukemia); and the like. Preferably, the cancer to be treated is a leukemia. The formulations can be used alone or in
20 combination with other chemotherapeutics. The dose of the composition of the invention to be administered, whether a single-unit dose, multi-unit dose, or a daily dose, will of course vary with the particular analog or derivative employed based on potency, administration route, patient
25 weight, and the nature of the patient's condition. The actual administered amount is to be decided by the supervising physician and may depend on multiple factors, such as, the age, condition, file history, etc., of the patient in question.

30 The dose can be determined by a physician upon conducting routine experiments. Prior to administration to humans, the efficacy is preferably shown in animal models.

Any animal model for cancer, preferably leukemia, known in the art can be used.

5 The subject, or patient, to be treated using the methods of the invention is an animal, e.g., a mammal, and is preferably human, and can be a fetus, child, or adult.

10 Preferably, the formulations of the invention are administered parenterally (intravenously, subcutaneously, intramuscularly, intraspinally, intraperitoneally, and the like). For parenteral administration, the formulations of the invention will normally be formulated as a solid, liquid, semisolid, gel, suspension, emulsion, or solution that, can be diluted in an aqueous medium to a concentration suitable for administration. The formulations of the invention can also be administered transdermally.

15 The present formulations can include additional pharmaceuticals and thus can serve as base formulation for polypharmacy. Such additional pharmaceuticals can be included and distributed in the formulation or added to the formulation prior to administration. For example, the formulations of the invention and other pharmaceuticals can be combined in an i.v. bag prior to administration. Additional pharmaceuticals can, for example, other chemotherapeutics.

25 The formulations of the invention can include additional suitable, pharmaceutically acceptable excipients. Preferred additional excipients, are those listed in the Physician's Desk Reference, 54th edition, 881-887, Medical Economics Company (2000), i.e., water, aqueous vehicles such as saline, Ringer's solution, or dextrose solution. Other examples of suitable excipients, such as binders and fillers are listed in *Remington's Pharmaceutical Sciences*, 18th Edition, ed. Alfonso Gennaro, Mack Publishing Co. Easton, PA, 1995 and *Handbook of Pharmaceutical Excipients*, 3rd

Edition, ed. Arthur H. Kibbe, American Pharmaceutical Association, Washington D.C. 2000, both of which are incorporated herein by reference. Whatever excipient is incorporated into the present formulations, preferably, that
5 excipient is sterile when added, or sterilized during the same process that sterilizes the formulation.

For parenteral administration as an aqueous solution, preferably, the present formulations are suitably buffered and isotonic. Furthermore, for parenteral
10 administration, the formulations of the invention should be sterile. An embodiment of the present invention includes a sterilization step. The sterilization may be carried out in several ways, e.g., by using a bacteriological filter, by incorporating sterilizing agents into the composition, by
15 irradiation, or by heating. Sterilization may be effected, for example, by filtration, e.g., through a 0.2 μm pore size filter. Other methods of sterilizing known to those skilled in the art can also be employed. Suitable sterile and non-sterile excipients are commercially available from: EM
20 Industries, Inc., Hawthorne, NY.; J.T Baker, Inc., Hayward, CA; Spectrum Quality Products, Inc., Gardena CA; Fisher Scientific International, Inc., Hampton NH; Aldrich Chemical Co., Inc., Milwaukee WI; Abbott Laboratories, Inc., North Chicago IL; Baxter Healthcare Corporation, Deerfield IL; and
25 Amresco, Inc., Cleveland OH.

To formulate aqueous parenteral dosage forms for injection, an aqueous medium, e.g., physiological saline or purified water, paclitaxel solubilizers, and any additional components are mixed in sanitized equipment, filtered, and
30 packaged according to well known methods in the art (for a discussion see e.g., *Remington's Pharmaceutical Sciences*, Alfonso R. Gennaro ed., Mack Publishing Co. Easton, PA, 19th ed., 1995, Chapter 87). A formulation of the invention can

by prepared in sterile form, such as a sterile solid, liquid, semisolid, gel, suspension, emulsion, or solution, preferably, as a sterile liquid concentrate that can be dissolved or dispersed in a sterile aqueous medium or any other injectable sterile medium prior to parenteral administration.

To formulate and administer transdermal dosage forms, well known transdermal delivery mediums such as lotions, creams, and ointments and transdermal delivery devices such as patches can be used (Ghosh, T.K.; Pfister, W.R.; Yum, S.I. *Transdermal and Topical Drug Delivery Systems*, Interpharm Press, Inc. p. 249-297, incorporated herein by reference). For example, a reservoir type patch design can comprise a backing film coated with an adhesive, and a reservoir compartment comprising a formulation of the invention, that is separated from the skin by a semipermeable membrane (e.g., U.S. Patent 4,615,699, incorporated herein by reference). The adhesive coated backing layer extends around the reservoir's boundaries to provide a concentric seal with the skin and hold the reservoir adjacent to the skin.

Gels, semisolids, and solid forms, containing the active can be prepared according to well known methods. For instance, by mixing in a standard V-blender, preferably, under anhydrous conditions. The homogeneous mixture can be passed through a screen mesh if desired. A comprehensive discussion on formulating solid forms is presented in *Remington's Pharmaceutical Sciences*, Alfonso R. Gennaro ed., Mack Publishing Co. Easton, PA, 19th ed., 1995, Chapter 92, incorporated herein by reference.

The dosage form of the invention may be provided in single-unit dose container forms or multi-unit-dose container forms by aseptically filling suitable containers

with the sterile solution to a prescribed active content as described above. It is intended that these filled containers will allow rapid dissolution of the composition upon reconstitution with appropriate sterile diluents *in situ*, giving an appropriate sterile solution of desired active concentration for administration. As used herein, the term "suitable containers" means a container capable of maintaining a sterile environment, such as a vial, capable of delivering a vacuum dried product hermetically sealed by a stopper means. Additionally, suitable containers implies appropriateness of size, considering the volume of solution to be held upon reconstitution of the vacuum dried composition; and appropriateness of container material, generally Type I glass. The stopper means employed, e.g., sterile rubber closures or an equivalent, should be understood to be that which provides the aforementioned seal, but which also allows entry for the purpose of introduction of diluent, e.g., sterile Water for Injection, USP, Normal Saline, USP, or 5% Dextrose in Water, USP, for the reconstitution of the desired active solution. These and other aspects of the suitability of containers for pharmaceutical products such as those of the invention are well known to those skilled in the practice of pharmaceutical arts.

The present invention will be further understood by reference to the following non-limiting examples. The following examples are provided for illustrative purposes only and are not to be construed as limiting the invention's scope in any manner.

IV. EXAMPLES**Example 1. Labd-13-ene, 8 α -ol, 15-yl acetate**

Labd-13-ene, 8 α , 15 diol (I) (50 mg) was dissolved in 2 ml of Ac₂O - Py (acetic anhydride-pyridine) for 48 hours at room temperature. The reaction mixture evaporated in vacuum to remove the solvents. The purity as well the identification of the compound labd-13-ene, 8 α -ol, 15-yl acetate was tested by TLC (Thin Layer Chromatography) and GC-MS (Gas Chromatography-Mass Spectrometry), using chromatography data. Compound was obtained in its pure state (47 mg).

Example 2. Labd-13-ene-8 α -ol 15-yl - β (or - α)-D (or -L)-pyrano (or furano)sides as monosaccharides or as disaccharides

Labd-14-ene-8 α -ol 13-yl- β (or - α)-D (or -L)-pyrano (or furano)sides as monosaccharides or as disaccharides.

3-yl- β (or - α)-D (or -L)-pyrano (or furano)sides as monosaccharides or as disaccharides, Labd-14-ene, 8, 13-epoxy. As an example

Condensation of Labd-13-ene-8 α , 15-diol (I) with 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide was carried out in a two-phase system consisting of chloroform-1.25M aqueous potassium hydroxide solution and benzyltriethylammonium bromide as catalyst. After a simple work up, followed by column chromatography, the labdane glycosides were isolated in 30% yield.

Example 3. Thiomidazolide derivative of 3 β -hydroxy -labd-14-ene-8, 13-epoxy

3 β -hydroxy -labd-14-ene-8, 13-epoxy, was converted to its thiomidazolide (45% yield) by treatment with N, N'-

thiocarbonyldiimidazole (Rasmunssen, J.R. (1980) J.Org. Chem. 45, 2725-2727).

Example 4. Preparation of Liposomes

5 Liposomes containing encapsulated or incorporated compounds I, II, III (Formulas I, II, III) and their derivatives, were prepared according to methods previously described (Juliano, R. L., Stamp, D. Biochem. Biophys. Res. Commun. 63, 651 (1975)).

10 In brief, lipid of 5 mg DMPC was dissolved in organic solvent (i.e chloroform) and then was evaporated under vacuum into the well of glass tube.

Compounds I, II, III (Formulas I, II, III) at 10% molar ratio were dissolved in chloroform and mixed with
15 the lipid prior to evaporation. In order to form liposomes, 1 ml of iso-osmotic buffer (TES 100 m M +NaCl 100 m M) p H = 7.5 and 300 mOs was added to the dried lipid film, and the mixture was dispersed by vortex with continuous temperature control; the usual temperature for preparation of liposomes
20 was 35 o C. In order to reduce the size of the liposomes the resultant large vesicles were extruded ten times through an extruder device with polycarbonated membrane with a pore size of 200 nm. The liposomes were passed through Sephadex G-75 to remove the free compound in all cases.

25 The liposomal composition was:

1. DMPC 10 mg in 2 ml TES 100 m M + NaCl 100 m M.
 - a. 5 mg DMPC/compound I (formula I) (0.25 mg)
 - b. 5 mg DMPC/compound II (formula II) (0.25 mg)
 - c. 5 mg DMPC/compound III (formula III) (0. 25 mg)

30 The drug concentration in all cases was 250 µg/ml

The results showed that into the above composition of liposomes the encapsulation was >80%. The retention of

the compounds into this particular liposome formulation was studied and found to be time dependent.

Example 5. Cytotoxic activity of labd-13-ene-8 α , 15-diol encapsulated in liposomal carriers

The following pharmacological methods were used for the evaluation of the biological activities of the compounds of the invention.

Cell cultures

Human cancer cell lines were used for in vitro drug testing. The cells were maintained as exponentially proliferating suspension cultures in RPMI-1640 medium (supplemented with 10% heat inactivated foetal calf serum, 2mM L-Glutamine and 50 μ g/ml gentamycin and incubated at 37 °C, in a humidified atmosphere with 5% CO₂. Peripheral blood mononuclear cells (PBML) were also isolated from normal donors using the Ficoll-Hypaque method and cultured as the cancer cell lines.

Cytotoxic activity

To determine the cytotoxicity, log-phase cells from each cell line, resting and activated PBML (1x10⁶ cells/ml), were incubated with free compound or liposomal formulation for 48 h, in 96-well flat-bottomed micro plates.

The initial inoculation densities for each cell line are presented in table (1) and were determined taking into account cell mass and growth rate (Monks A., Scudiero D., Skehan P., Shomaker R., Paull K., Vistica D., Hose C et al. Feasibility of a High-Flux Anticancer Drug screen using a diverse panel of cultured human tumor cell lines. JNCI 1991; 83(11): 757-766 Paul KD, Shomaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L., Plowman J and Boyd MR. Tumor Cell Lines: Development of Mean Graph and Compare Algorithm. JNCI 1989; 81(14): 1088-1092). Viability of the cells was

assessed by trypan blue dye exclusion, at the beginning of the experiment and was always greater than 98%.

Cells were added at the appropriate inoculation densities in 96-well micro titer plates and preincubated for 24 hours in a moist atmosphere of 5% CO₂ in air at 37°C, to allow stabilization prior to addition of the test compounds. To determine their activity, the free compound or liposomal formulation were added at the same time to each cell line. Cultures, where an equivalent amount of DMSO was added, used as controls. After the addition of the test agents the cells were cultured in micro plates for an additional 48 h under the same conditions. Each test agent was inoculated at five concentrations (10⁻⁴ to 10⁻⁸ M). The activity for each compound on each cell line was determined by the MTT method with modifications. Briefly 4 h before the end of the 48h incubation period, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma-Aldrich) dissolved in PBS (Phosphate buffered saline), was added in the cell cultures to give a final concentration of 50 µg/ml. At the end of the 48 h incubation period, DMSO was added to the wells and the optical density was measured with an ANTHOS HT II Microelisa reader, using a test wavelength of 550 nm.

The data represent the means of experiments done in triplicates and were analyzed using a two-tailed Student's t-test.

Three parameters GI₅₀, TGI and LC₅₀ were estimated using the MTT method. Briefly GI₅₀ is the concentration where $100 \cdot (T - T_0) / (C - T_0) = 50$ and measures the growth inhibitory power of the test compound. TGI is the concentration of the test agent where $100 \cdot (T - T_0) / (C - T_0) = 0$ and measures the cytostatic effect. Finally LC₅₀ is the concentration of the drug where $100 \cdot (T - T_0) / T_0 = -50$ and measures the cytotoxic effect of the drug. At the above

formulas used for the calculation of the three parameters, T is the optical density of the test well after a 48h period of exposure to test compound; T0 is the optical density at the time zero (when the drug is added) and C is the optical density of the control well (cells incubated for 48h with no additives).

Results

The leukemic cell lines CCRF-CEM, MOLT4, HUT78 (T cells), RPMI 8226 (B cell line), HL60 (promyelocytic cell line), K562 (proerythrocytes) and the multi- drug resistant (MDR) cell lines: CCRF-CEM/C2, HL60/MX1 and HL601MX2 were used. All cell lines were grown and tested for viability as described above. Free compounds and encapsulated (as described above) were tested according to the method described under cytotoxic activity (see Biological activity, above). They were also tested for cytotoxicity as described in Biological Activity against normal PBML resting or activated by the addition of 5 μ g/ml PHA-P. Results for free labd-13-ene-8 α , 15-diol (means of GI50, TGI, LC50) expressed in μ M are summarized in Table 1 while of encapsulated in liposomes in Tables 2 and 3.

TABLE 1

	Labd-13-ene-8, 15 diol	GI50	TGI	LC50
5	CCRF-CEM	75.74	141.08	200
	CCRF-CEM/C2	42.27	74.96	107.65
	MOLT4	32.32	76.22	120.11
	HUT78	109.14	186	200
	RPMI 8226	42.2	80.08	117.96
	K562	87.08	159	200
10	HL60	47.69	69.74	91.8
	HL60/MX1	52.32	80.1	107.87
	HL601/MX2	43.81	73.14	102.48
	MEAN	59.15	104.48	138.65
	PBML (resting)	>>100	>>100	>>100
15	PBML (stimulating)	66.2	>>100	>>100

TABLE 2

Labd-13-ene-8, 15 diol, DPPC	GI50	~TGI	LC50
CCRF-CEM	28.74	52.23	75.72
CCRF-CEM/C2	19.12	46.55	73.99
MOLT4	24.61	52.41	80.21
HUT78	13.98	49.41	83.39
RPMI 8226	5.48	38.72	75.54
K562	35.30	78.84	122.39
HL60	33.92	56.36	78.80
HL60/MX1	18.54	46.17	73.79
HL601/MX2	0.62	17.81	61.78
MEAN	20.03	48.72	80.62

TABLE 3

Labd-13-ene-8, 15 diol, DMPC	GI50	~TGI	LC50
CCRF-CEM	28.56	51.93	75.30
CCRF-CEM/C2	5.14	10.41	55.36
MOLT4	29.72	54.75	79.78
HUT78	6.04	28.65	66.19
RPMI 8226	7.98	38.20	73.70
K562	27.24	58.60	89.95
HL60	32.63	55.21	77.80
HL60/MX1	26.18	50.87	75.57
HL601/MX2	1.65	8.36	49.79
MEAN	18.35	39.66	71.49

The effect of the above used formulations against the MDR cell lines are summarized in table 4. The Resistant Factor (RF) is defined as follows: GI50 of the MDR daughter

cell line / GI50 of the parental cell line. The (-) represents a parental cell line more resistant than the daughter MDR line.

TABLE 4

RF (GI50)	CCRF CEM/C2	HL 60/MX1.1	HL60/MC2
Labd-13-ene-8 α , 15 diol	0.6	1.1	0.9
/DPPC	0.6	-2	-55
/DMPC	-6	1	-20

Labd-13-ene-diol was also tested at 100 μ M against NCI-H460, MCF-7 and SF-268 (one dose primary assay). The results are summarized below (Table 5). Minus symbol denotes cytotoxic activity.

TABLE 5

Concentration	Growth Percentages		
	NCI-H460 (Lung cancer)	MCF-7 (Breast cancer)	SF-268 (CNS cancer)
100 μ M	-80	-89	-88

Example 6. Cytotoxic activity of labd-14-ene-8, 13-diol encapsulated in liposomal carriers

Labd-14-ene-8, 13-diol was also encapsulated into liposomes as described above and tested as labd-13-ene-8 α , 15-diol. Results are presented in the corresponding tables below (Tables 6-10)

TABLE 6

Labd-14-ene-8, 13 diol	GI50	TGI	LC50
CCRF-CEM	35.00	60.00	85.00

	Labd-14-ene-8, 13 diol	GI50	TGI	LC50
	CCRF-CEM/C2	29.05	52.41	75.78
	MOLT4	31.60	54.66	77.72
	HUT78	33.68	56.09	78.49
	RPMI 8226	14.94	42.84	70.73
5	K562	35.58	57.45	79.33
	HL60	41.48	60.72	79.95
	HL60/MX1	42.94	61.90	80.86
	HL601/MX2	31.41	54.12	76.83
	MEAN	32.85	55.58	78.30
10	PBML (resting)	34.6	63.8	93.1
	PBML (stimulating)	33.1	61.0	89.0

TABLE 7

15	Labd-14-ene-8, 13 diol, DPPC	GI50	TGI	LC50
	CCRF-CEM	33.34	56.03	78.72
	CCRF-CEM/C2	32.10	55.24	78.38
	MOLT4	28.43	55.50	82.58
20	HUT78	6.22	42.52	79.81
	RPMI 8226	5.10	45.58	82.62
	K562	55.67	113.74	171.80
	HL60	39.50	59.98	80.46
	HL60/MX1	7.65	33.05	66.51
25	HL601/MX2	2.21	8.78	54.00
	MEAN	23.36	52.27	86.10

TABLE 8

Labd-14-ene-8, 13 diol, DMPC	GI50	TGI	LC50
CCRF-CEM	43.15	68.64	94.14
CCRF-CEM/C2	30.50	57.03	83.57
MOLT4	61.02	127.90	194.78
HUT78	4.18	27.78	71.43
RPMI 8226	37.99	67.33	96.68
K562	53.48	105.24	157.01
HL60	58.12	89.87	121.62
HL60/MX1	37.36	75.36	113.36
HL601/MX2	28.71	61.37	94.02
MEAN	39.39	75.61	114.07

TABLE 9

RF (GI50)	CCRF CEM/C2	HL 60/MX1.1	HL60/MC2
Labd-13-ene-8 α , 15 diol	0.8	1	0.8
/DPPC	0.97	-5	-18
/DMPC	0.7	0.64	-2

Example 7. Cytotoxic activity of labd-13-ene-8 α , 15-yl acetate

The cytotoxic activity of the derivative of Labd-13-ene-8 α , 15-diol i.e. labd-13-ene-8 α , 15-yl acetate was also assayed in the same manner as described above (Tables 10-13)

TABLE 10

Labd-13-ene-8, 15-yl acetate	GI50	TGI	LC50
CCRF-CEM	69.09	128.17	187.00

	Labd-13-ene-8, 15-yl acetate	GI50	TGI	LC50
	CCRF-CEM/C2	46.77	78.83	110.88
	MOLT4	42.80	89.95	137.10
	HUT78	95.18	164.00	200.00
	RPMI 8226	41.31	68.43	95.55
5	K562	78.19	162.00	200.00
	HL60	44.79	67.04	89.29
	HL60/MX1	53.92	80.14	106.36
	HL601/MX2	38.78	69.90	101.03
	MEAN	56.76	100.94	136.36
10	PBML (resting)	>>100	>>100	>>100
	PBML (stimulating)	65.9	>>100	>>100

TABLE 11

	Labd-13-ene-8, 15-yl acetate, DPPC	GI50	TGI	LC50
15	CCRF-CEM	31.52	53.40	75.28
	CCRF-CEM/C2	37.01	58.22	79.43
	MOLT4	32.39	56.62	80.85
	HUT78	20.60	52.18	83.76
20	RPMI 8226	33.97	65.74	97.52
	K562	76.94	164.92	252.91
	HL60	41.76	61.70	81.65
	HL60/MX1	9.60	40.58	71.56
	HL601/MX2	8.87	40.21	71.34
25	MEAN	32.52	65.95	99.37

TABLE 12

Labd-13-ene-8, 15-yl acetate, DMPC	GI50	TGI	LC50
CCRF-CEM	31.33	53.97	76.60
CCRF-CEM/C2	19.22	46.13	73.05
MOLT4	29.50	55.33	81.16
HUT78	4.60	25.63	65.04
RPMI 8226	31.93	56.59	81.24
K562	63.86	131.28	198.70
HL60	37.66	61.22	84.77
HL60/MX1	14.17	45.20	76.23
HL601/MX2	23.69	49.63	75.56
MEAN	28.44	58.33	90.26

TABLE 13

RF (GI50)	CCRF CEM/C2	HL 60/MX1.1	HL60/MC2
Labd-13-ene-8 α , 15- yl acetate	0.7	1.2	0.9
/DPPC	1.15	-4	-5
/DMPC	0.61	-2.7	0.6

Conclusion

The free and in liposome encapsulated labdanes are cytotoxic against cancer cell lines and are not affected by the multi-drug-resistance phenotype of the cell lines tested. They also exhibit reduced cytotoxicity against normal, resting or activated, human PBML.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed,


various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

5

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:
a therapeutically effective amount at least one compound of
Formula 1, mixtures thereof or a plant extract containing at
least one compound of Formula 1 or mixtures thereof,



Formula 1

wherein R is selected from the group consisting of H,
alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl,
cycloalkylcarbonyl, aralkylcarbonyl, alkyl, alkenyl,
alkynyl, cycloalkyl, aralkyl, dialkylaminoalkyl,
alkylthioketones, alkenylthioketones, alkynylthioketones,
cycloalkylthioketones, aralkylthioketones,
heterocyclylthioketones and sugars; and a carrier or
diluent.


2. The pharmaceutical composition according to claim
1, wherein the pharmaceutical composition is formulated for
enteral, parenteral and topical use.

3. The pharmaceutical composition according to claim
1, wherein the pharmaceutical composition is encapsulated in
the internal part of lipidic lamellar phases or liposomes,
or incorporated into lipid bilayers of lipidic lamellar
phases or liposomes.

4. The pharmaceutical composition according to any
one of claims 1, 2 or 3, wherein the pharmaceutical

composition is formulated for treating a subject with a disease or disorder related to cancer.

5. A pharmaceutical composition, comprising: a therapeutically effective amount at least one compound of Formula 2, mixtures thereof or a plant extract containing at least one compound of Formula 2 or mixtures thereof,



Formula 2


wherein R is selected from the group consisting of H, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, cycloalkylcarbonyl, aralkylcarbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, dialkylaminoalkyl, alkylthioketones, alkenylthioketones, alkynylthioketones, cycloalkylthioketones, aralkylthioketones, heterocyclylthioketones and sugars; and a carrier or diluent.

6. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is formulated for enteral, parenteral and topical use.

7. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is encapsulated in the internal part of lipidic lamellar phases or liposomes, or incorporated into lipid bilayers of lipidic lamellar phases or liposomes.

8. The pharmaceutical composition according to any one of claims 5, 6 or 7, wherein the pharmaceutical composition is formulated for treating a subject with a disease or disorder related to cancer.

9. A pharmaceutical composition, comprising: a therapeutically effective amount at least one compound of Formula 3, mixtures thereof or a plant extract containing at least one compound of Formula 3 or mixtures thereof,



III

wherein R₁ is selected from the group consisting of =O, OR₂, or a halogen selected from the group consisting of chlorine, bromine or iodine, and wherein R₂ is selected from the group consisting of H, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, cycloalkylcarbonyl, aralkylcarbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, dialkylaminoalkyl, alkylthioketones, alkenylthioketones, alkynylthioketones, cycloalkylthioketones, aralkylthioketones, heterocyclylthioketones and sugars; and a carrier or diluent.

10. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is formulated for enteral, parenteral and topical use.

11. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is encapsulated in the internal part of lipidic lamellar phases or liposomes, or incorporated into lipid bilayers of lipidic lamellar phases or liposomes.

12. The pharmaceutical composition according to any one of claims 9, 10 or 11, wherein the pharmaceutical composition is formulated for treating a subject with a disease or disorder related to cancer.

13. A method of treating a subject with cancer comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of any one of claims 1-12.

14. The method of claim 13, wherein the cancer is a leukemia.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number
WO 01/34116 A3

(51) International Patent Classification⁷: **A61K 9/127**,
35/78, 31/352, 31/222, 31/045, A61P 35/00

KOKKINOPOULOS, Demetrios; 26 Naxou Str.,
GR-145 62 Kifissia (GR).

(21) International Application Number: PCT/GR00/00033

(74) Agent: **PAPACONSTANTINO, Helen, G.**; 2 Coumbari
Street, GR-106 74 Athens (GR).

(22) International Filing Date:
8 November 2000 (08.11.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ,
EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PL, RO, RU, SD, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
990100387 8 November 1999 (08.11.1999) GR

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(71) Applicant: **P.N. GEROLYMATOS S.A.** [GR/GR]; 13
Asklipiou Street, GR-145 68 Kryoneri Attica (GR).

Published:
— with international search report

(72) Inventors: **DEMETZOS, Constantinos**; 523 Grigo-
riou Labraki Str., GR-187 57 Keratsini (GR). **DIMAS,**
Constantinos; 74-78 Kanari Str., GR-185 38 Piraeus
(GR). **ANGELOPOULOU, Demetra**; 33 Kalirois Str.,
GR-145 65 Ekali (GR). **ANASTASSAKI, Thalia**; 27
Hatziantoniou Str., GR-151 24 Amaroussion (GR).

(88) Date of publication of the international search report:
22 November 2001

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATIONS COMPRISING LABDANES FOR THE TREATMENT OF TUMORS OR
LEUKEMIAS

(57) Abstract: The present invention relates to novel compositions based on hydrated lipidic lamellar phases or liposomal com-
positions, prepared by combining different lipid molecules, synthetic and/or from natural sources, said compositions comprising
at least one of a) labd-13-ene-8 α , 15-diol and/or derivatives thereof; b) labd-14-ene-8, 13-diol or derivatives thereof; c) 3 β -hy-
droxy-labd-14-ene-8, 13-epoxy and/or derivatives thereof; d) a plant extract containing the aforementioned labdenes or derivatives
thereof. The compositions of the invention exhibit cytotoxicity against cancerous cells and are utilized for the treatment of tumors
and leukemias.

WO 01/34116 A3



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GR 00/00033

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/127 A61K35/78 A61K31/352 A61K31/222 A61K31/045
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DIMAS K ET AL.: "Cytotoxic activity of labdane type diterpenes against human leukemic cell lines in vitro." PLANTA MEDICA, vol. 64, no. 3, April 1998 (1998-04), pages 208-211, XP000997965 ISSN: 0032-0943 cited in the application page 208, right-hand column, last paragraph -page 209, left-hand column, paragraph 1 page 209, left-hand column, paragraph 5 -right-hand column, paragraph 1; figure 1; table 1 page 211, left-hand column, paragraphs 3,4 --- -/--	1,2,4,9, 10,12-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

23 July 2001

Date of mailing of the international search report

14/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

In ternational Application No
PCT/GR 00/00033

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DEMETZOS C ET AL.: "Natural metabolites of ent-13-epi-manoyl oxide and other cytotoxic diterpenes from the resin "Ladano" of Cistus creticus"</p> <p>PLANTA MEDICA, vol. 60, 1994, pages 590-591, XP000198291 ISSN: 0032-0943 page 590, right-hand column, last paragraph -page 591, left-hand column, paragraph 2; figures; table 1</p> <p>---</p>	1,2,4,9, 10,12-14
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 1999 (1999-03)</p> <p>DIMAS K ET AL.: "The effect of sclareol on growth and cell cycle progression of human leukemic cell lines."</p> <p>Database accession no. PREV199900162940 XP002168140 abstract & LEUKEMIA RESEARCH, vol. 23, no. 3, March 1999 (1999-03), pages 217-234, ISSN: 0145-2126 cited in the application</p> <p>---</p>	5,6,8, 13,14
X	<p>CHINOI I ET AL.: "Cytotoxic and antibacterial labdane-type diterpenes from the aerial parts of Cistus incanus subsp. creticus"</p> <p>PLANTA MEDICA, vol. 60, no. 1, 1994, pages 34-36, XP000645961 ISSN: 0032-0943 page 34, right-hand column, last paragraph -page 35, left-hand column, paragraph 2; figure 1; tables 1,2</p> <p>---</p>	1,2,4-6, 8,13,14
X	<p>KALPOUTZAKIS E ET AL.: "Antibacterial labdane-type diterpenes from the resin "Ladano" of Cistus creticus subsp. creticus"</p> <p>NATURAL PRODUCT LETTERS, vol. 11, 1998, pages 173-179, XP002118280 ISSN: 1057-5634 page 175, last paragraph -page 177, paragraph 1; figures; table 1</p> <p>---</p>	1,2,4,9, 10,12
A	<p>WO 91 02525 A (LVMH RECH) 7 March 1991 (1991-03-07) cited in the application page 3, line 26 -page 6 examples claim 1</p> <p>-----</p>	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

In: .tional Application No

PCT/GR 00/00033

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9102525 A	07-03-1991	FR 2650953 A	22-02-1991
		AT 93389 T	15-09-1993
		CA 2062745 A	18-02-1991
		DE 69002951 D	30-09-1993
		DE 69002951 T	24-03-1994
		EP 0487603 A	03-06-1992
		ES 2060197 T	16-11-1994
		JP 5503287 T	03-06-1993
		US 5510113 A	23-04-1996
		US 5891464 A	06-04-1999
		US 5384126 A	24-01-1995
